Unknown Analyst

And today, they're a great privilege to have Moderna as part of our 2026 Global Healthcare Conference. Representing the company, we have Lavina Talukdar as Head of Investor Relationship here. Lavina, thanks so much for joining us. How are you doing today?

Lavina Talukdar
Senior VP & Head of Investor Relations

Great. Thank you so much for having us.

Unknown Analyst

That's awesome. Yes. We have a long list of questions here. But maybe before we go into the individual programs, let's start big picture. Can you maybe talk about what progress has Moderna made over the last few months? And maybe most importantly, what's ahead here for Moderna?

Lavina Talukdar
Senior VP & Head of Investor Relations

Sure. Great question. So I'll start with like the foundations that have been laid in 2025. So we entered that year with a little bit of uncertainty given the change in administration and the transition that was taking place. However, we try to control what we can control and costs came out of the infrastructure pretty significantly. We set a goal to take out $1 billion in cash costs, and we took out $2 billion.

And we also ended the year at the high end of our revenue guidance of $1.9 billion in sales, which I think, again, makes a really good foundation or establishes what we did in the first quarter of this year, also continuing on cost containment and beating sales expectations, mainly driven by where we see growth drivers this year, the ex U.S. strategic partnerships as well as mNEXSPIKE later in the fall to be continuing to drive growth for us.